Biomaterial Database

Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. 1997

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, Germany.

UI	MeSH Term	Description	Entries
D007166	Immunosuppressive Agents	Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.	Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009402	Nephrosis, Lipoid	A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.	Glomerulonephritis, Minimal Change,Glomerulopathy, Minimal Change,Nephropathy, Minimal Change,Nephrotic Syndrome, Minimal Change,Idiopathic Minimal Change Nephrotic Syndrome,Minimal Change Disease,Minimal Change Glomerulopathy,Minimal Change Nephrotic Syndrome,Change Diseases, Minimal,Disease, Minimal Change,Diseases, Minimal Change,Glomerulonephritides, Minimal Change,Glomerulopathies, Minimal Change,Lipoid Nephroses,Lipoid Nephrosis,Minimal Change Diseases,Minimal Change Glomerulonephritides,Minimal Change Glomerulonephritis,Minimal Change Nephropathies,Minimal Change Nephropathy,Nephropathies, Minimal Change,Nephroses, Lipoid
D004351	Drug Resistance	Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.	Resistance, Drug
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000305	Adrenal Cortex Hormones	HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE.	Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex
D016559	Tacrolimus	A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.	Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D016572	Cyclosporine	A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome.

November 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Steroid-resistant minimal change nephrotic syndrome in Waldenström macroglobulinemia.

March 2013, Annals of hematology,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

[Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment].

January 1996, Nihon Jinzo Gakkai shi,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.

June 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Cyclosporin in steroid-resistant nephrotic syndrome.

November 1994, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome.

June 2006, Clinical nephrology,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Cyclosporin in steroid-resistant idiopathic nephrotic syndrome.

January 1995, Contributions to nephrology,

F Schweda, and R Liebl, and G A Riegger, and B K Krämer

Cyclosporin in frequently relapsing minimal change nephrotic syndrome.

August 1986, Lancet (London, England),